Safety and Efficiency of γ9δ2 T Cell Against Post-transplant Acute Leukemia/Myelodysplastic Syndrome Relapse
Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This study investigates the potential curative properties of ex-vivo expanded γ9δ2 T-cells
obtained from a suitable donor for patients with relapsed acute leukemia or myelodysplastic
syndrome after allogeneic hematopoietic stem cell transplantation.